Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CALML3 | P27482 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020719 | 0.87 | MAOA (0.42) | MAOAKCNH2MAOBCALML3CYP3A4 | |
| SCHEMBL4016060 | 0.86 | MAOA (0.44) | MAOAKCNH2MAOBCALML3CYP3A4 | |
| SCHEMBL4013870 | 0.84 | MAOA (0.57) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL6181295 | 0.82 | MAOA (0.40) | MAOAKCNH2MAOBCALML3CYP3A4 | |
| SCHEMBL5216698 | 0.76 | MAOA (0.58) | MAOAMAOBCALML3 | |
| SCHEMBL4015683 | 0.73 | MAOA (0.53) | MAOAKCNH2MAOBCALML3CYP3A4 | |
| SCHEMBL4017450 | 0.73 | MAOA (0.59) | MAOAKCNH2MAOBCALML3CYP3A4 | |
| SCHEMBL13939886 | 0.73 | MAOA (0.61) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL4014454 | 0.73 | MAOA (0.61) | MAOAKCNH2MAOBCYP3A4CYP2D6 | |
| SCHEMBL6308918 | 0.72 | MAOB (0.43) | MAOAMAOBCALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | claimed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | claimed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | H1-0, NGLY1, H1-5 | MAOA 1576/4885KCNH2 632/4885MAOB 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.